Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04993261 | An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | active not recruiting | Early Phase 1 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07132645 | An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer | recruiting | Early Phase 1 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 31, 2026 |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | recruiting | Early Phase 1 | 30 | Eben RosenthalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07460232 | FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease | recruiting | Early Phase 1 | 50 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04510311 | Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors | completed | Early Phase 1 | 32 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04544098 | Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver | active not recruiting | Early Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07568366 | AI in Endoscopic Transsphenoidal Surgery | not yet recruiting | Early Phase 1 | 30 | University College, LondonOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06148636 | A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 24 | David BushnellOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03335670 | Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 30 | Yusuf MendaOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05111509 | A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent | active not recruiting | Early Phase 1 | 20 | Yusuf MendaOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT01873248 | Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective | completed | Early Phase 1 | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT05359146 | Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)(Beta plus) | unknown | Early Phase 1 | 16 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05069220 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | recruiting | Early Phase 1 | 150 | Peking Union Medical College HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03724409 | Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases | terminated | Early Phase 1 | 3 | Sandeep LaroiaOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT05871320 | Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms(TECANT) | completed | Early Phase 1 | 10 | Jagiellonian UniversityOTHER | 3 | Sep 29, 2023 | clinicaltrials |
| NCT04897542 | Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors | unknown | Early Phase 1 | 100 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT03623984 | Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers | withdrawn | Early Phase 1 | 0 | University of Alabama at BirminghamOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03044977 | Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 20 | David BushnellOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05034783 | [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients | unknown | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT02823691 | The MetNET-2 Trial(MetNET-2) | unknown | Early Phase 1 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT03001349 | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | terminated | Early Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT03197012 | Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor | completed | Early Phase 1 | 10 | Thomas HopeOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04440956 | An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours | completed | Early Phase 1 | 10 | Clarity Pharmaceuticals LtdINDUSTRY | 0 | Jun 22, 2020 | clinicaltrials |
| NCT04185350 | Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma | unknown | Early Phase 1 | 60 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT04041882 | 68Ga-DOTATATE PET/CT in Neuroendocrine Tumor | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02560376 | 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Sep 25, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Aug 11, 2026source: clinicaltrials